Current Report Filing (8-k)
October 01 2014 - 9:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2014
ENANTA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-35839 |
|
04-3205099 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
500 Arsenal Street, Watertown, Massachusetts 02472
(Address of principal executive offices and zip code)
(617) 607-0800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.02 Termination of a Material Definitive Agreement.
On September 30, 2014, Enanta Pharmaceuticals and Novartis Institutes for Biomedical Research entered into an amendment to their
Collaboration and License Agreement entered into effective as of February 16, 2012, as amended, in light of Novartis determination that hepatitis C is no longer a strategic focus of Novartis. The amendment provides for termination of the
collaboration and transition of EDP-239 and the other NS5A inhibitor compounds developed under the collaboration back to Enanta, as well as completion or transition of specified proof-of-concept clinical studies currently underway involving EDP-239,
and a combination study with EDP-239 and Alisporivir, a cyclophilin inhibitor licensed by Novartis from Debiopharm. The amendment also includes an option for Enanta to purchase from Novartis any unused API and drug product related to EDP-239.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: October 1, 2014 |
|
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Paul J. Mellett |
|
|
|
|
|
|
Paul J. Mellett |
|
|
|
|
|
|
Chief Financial Officer |
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024